Quantitative proteomic studies on TNBC in premenopausal patients

Abstract

The molecular mechanism of triple-negative breast cancer(TNBC) remains unclear, and there has been no effective targeted therapy for it. A better understanding of the mechanisms of TNBC is urgently needed to identify new therapeutic targets. In this study, eight cases of premenopausal TNBC patients were collected, and a comparative proteomic analysis of their breast cancer tissues and matched paraneoplastic ones was performed via isobaric tags for relative and absolute quantitation(iTRAQ) technology coupled with two-dimensional liquid chromatography-tandem mass spectrumetry(2D LC-MS/MS). The researches result in the identification of 1254 nonredundant proteins, of which 1243 proteins reached the strict quantitative standard. The quantitative comparison reveal that among the 214 proteins, 81 proteins significantly increased and 133 proteins decreased in TNBC tissues compared to corresponding ones in control. The Gene Ontology(GO) annotations and pathway analysis show their distributions in GO and the marked functions, as well as the closely related signal transduction pathways involved in extra cellular matrix (ECM)-receptor interaction, protein digestion and absorption, renin-angiotensin system, complement and coagulation cascades and focal adhesion. This pilot study will lay a foundation for further searching for therapeutic targets of TNBC and exploring the molecular mechanism, which can also be extended as a part of a large scale biomarker discovery plan.

Keywords

Triple-negative breast cancer(TNBC) / Proteomics / Isobaric tags for relative and absolute quantitation (iTRAQ) / Mass spectrometry

References

[1] Zhao J, Liu Y Q, Xu Y Z, Zhang Y F, Wu J G, Hou K Y, Zhao H M, Lei Y T, Zhou X S, Xu Z, Ling X F. Chem. J. Chinese Universities, 2011, 32(2): 246.

[2] Perou C M, Sørlie T, Eisen M B, van de Rijn M, Jeffrey S S, Rees C A, Pollack J R, Ross D T, Johnsen H, Akslen L A, Fluge O, Pergamenschikov A, Williams C, Zhu S X, Lønning P E, Børresen-Dale A L, Brown P O, Botstein D. Nature, 2000, 406(6797): 747.

[3] Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J S, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou C M, Lønning P E, Brown P O, Børresen-Dale A L, Botstein D. J. Proc Natl. Acad. Sci., 2003, 100(14): 8418.

[4] Peddi P F, Ellis M J, Ma C. Int. J. Breast Cancer, 2012, 10: 1155.

[5] Hudis CA, Gianni L. J. Oncologist, 2011, 16(Suppl.1): 1.

[6] Benueei F. Int. J. Cancer, 2008, 123(1): 236.

[7] Rakha E A, Elsheikh S E, Aleskandarany M A, Habashi H O, Green A R, Powe D G, El-Sayed M E, Benhasouna A, Brunet J S, Akslen L A, Evans A J, Blamey R, Reis-Filho J S, Foulkes W D, Ellis I O. ., Clinical Cancer Research, 2009, 15(7): 2302.

[8] Dent R, Trudeau M, Pritchard K I, Hanna W M, Kahn H K, Sawka C A, Lickley L A, Rawlinson E, Sun P, Narod S A. Clin. Cancer Res., 2007, 13: 4429.

[9] Ross P L, Huang Y N, Marchese J N, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin D J. Mol. Cell Proteomics, 2004, 3(12): 1154.

[10] Lu W D, Qiu J, Zhao G X, Qie L Y, Wei X B, Gao H Q. Chem. Res. Chinese Universities, 2012, 28(6): 1035.

[11] Sutton C W, Rustogi N, Gurkan C, Scally A, Loizidou M A, Hadjisavvas A, Kyriacou K. J. Proteome Res., 2010, 9(8): 3891.

[12] Bouchal P, Roumeliotis T, Hrstka R, Nenutil R, Vojtesek B, Garbis SD. J. Proteome Res., 2009, 8(1): 362.

[13] Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T, Yamanishi Y. Nucleic Acids Res., 2008, 36: 480.

[14] Weinstat-Saslow D L, Zabrenetzky V S, van Houtte K, Frazier W A, Roberts D D, Steeg P S. Cancer Res., 1994, 54: 6504.

[15] Chandrasekaran S, Guo N H, Rodrigues R G, Kaiser J, Roberts D D. J. Biol. Chem., 1999, 274(16): 11408.

[16] Hsu S, Qin H, Dickinson D, Xie D, Bollag W B, Stoppler H, Pearl H, Vu A, Watkins M. In vivo, 2007, 21(2): 279.

[17] Fang H Y, Chen C Y, Hung M F, Hsiao Y T, Chiang T C, Lin T Y, Chang H W, Chow K C, Ko W J. Oncol. Rep., 2011, 26(2): 359.

[18] Oxford G, Owens C R, Titus B J, Foreman T L, Herlevsen M C, Smith S C T D. Cancer Res., 2005, 65(16): 7111.

[19] Cancemi P, di Cara G, Albanese N N, Costantini F, Marabeti M R, Musso R, Lupo C, Roz E, Pucci-Minafra I. BMC Cancer, 2010, 10: 476.

[20] Lehmann B D, Bauer J A, Chen X, Sanders M E, Chakravarthy A B, Shyr Y, Pietenpol J A. J. Clin. Invest., 2011, 121(7): 2750.

[21] Krupp M, Maass T, Marquardt J U, Staib F, Bauer T, König R, Biesterfeld S, Galle P R, Tresch A, Teufel A. BMC Medical Genomics, 2011, 4: 53.

[22] Wei Z, Li H. Bioinformatics, 2007, 23(12): 1537.

[23] Namazi S, Monabati A, Ardeshir-Rouhani-Fard S, Azarpira N. Mol. Carcinog., 2010, 49(12): 1022.

[24] Du N, Feng J, Hu L J, Sun X, Sun H, Zhao Y, Yang Y P, Ren H. Oncol. Rep., 2012, 27(6): 1893.

[25] Ramírez-Expósito M J, Carrera-González M P, Mayas M D, Dueñas B, Martínez-Ferrol J, Martínez-Martos J M. Maturitas, 2012, 72(1): 79.

[26] Xi B, Zeng T, Liu L, Liang Y, Liu W, Hu Y, Li J. Breast Cancer Res. Treat., 2011, 130(2): 561.

[27] Vinson G P, Barker S, Puddefoot J R. Endocr. Relat. Cancer, 2012, 19(1): R1.